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A B S T R A C T   
Background: There is emerging evidence of long-term sequelae in a considerable proportion of COVID-19 patients 
after recovery and the spectrum and severity of such sequelae should be systematically reviewed. This review 
aims to evaluate the available evidence of all intermediate and long-term COVID-19 sequelae affecting formerly 
healthy adults. 
Methods: A systematic literature search of Embase, WHO, Scopus, Pubmed, Litcovid, bioRxiv and medRxiv was 
conducted with a cutoff date of the 17th September 2020 according to PRISMA guidelines and registered in 
PROSPERO (CRD42020208725). Search terms included “COVID-19”, “coronavirus disease 2019”, “SARS-CoV-2”, 
“sequelae” and “consequence*”. Publications on adult participants, with a confirmed SARS-CoV-2 infection were 
included. Elderly (>50 years old) and children (<18 years old) were excluded. Bias assessment was performed 
using a modified Newcastle-Ottawa Scale. 
Results: A total of 31 papers were included. Study types included prospective and retrospective cohort studies, 
cross-sectional studies and case reports. Sequelae persistence since infection spanned 14 days to three months. 
Sequelae included persistent fatigue (39–73% of assessed persons), breathlessness (39–74%), decrease in quality 
of life (44–69%), impaired pulmonary function, abnormal CT findings including pulmonary fibrosis (39–83%), 
evidence of peri-/perimyo-/myocarditis (3–26%), changes in microstructural and functional brain integrity with 
persistent neurological symptoms (55%), increased incidence of psychiatric diagnoses (5.8% versus 2.5–3.4% in 
controls), incomplete recovery of olfactory and gustatory dysfunction (33–36% of evaluated persons). 
Conclusions: A variety of organ systems are affected by COVID-19 in the intermediate and longer-term after 
recovery. Main sequelae include post-infectious fatigue, persistent reduced lung function and carditis. Careful 
follow-up post COVID 19 is indicated to assess and mitigate possible organ damage and preserve life quality.   
1. Introduction 
Although SARS-CoV-2 predominantly affects the respiratory system, 
several studies and interim reports indicate that COVID-19 is a multi-
system infection with both overt and subtle health consequences. Data 
on how long symptoms persist, the impact of such symptoms on 
everyday life and the short-term, intermediate and long-term sequelae of 
this infection have scarcely been researched. Most original data publi-
cations focus on patients who have been hospitalized, on individuals 
who have suffered severe illness or on older patients with co- 
morbidities. There are few studies following up on young people who 
have tested SARS-CoV-2 positive and who have experienced mild illness 
or indeed, been asymptomatic while testing positive. Such data are 
particularly important in terms of projecting the future burden of 
COVID-19 sequelae on healthcare systems and also in the context of 
“fitness to work” of young population groups as young adults constitute 
a large proportion of any country’s workforce. 
In the ongoing pandemic, evidence is emerging of individuals 
suffering from debilitating symptoms weeks and even months after 
COVID-19 diagnosis. This is of great concern to the medical community. 
The large number of such cases becomes apparent when looking at the 
size of groups such as the so called “COVID long haulers” on social media, 
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the members of such groups often number thousands [1]. Several small 
studies have followed up on recovered COVID-19 cases, particularly on 
severe cases. However, a systematic and evidence-based review on 
long-term COVID-19 sequelae in previously healthy adults is missing. 
In this systematic review, we identified and summarized original 
data published until mid-September 2020. The focus was on formerly 
healthy young to middle-aged adults. Children and elderly were 
excluded. Speculations on possible consequences, that may be antici-
pated in the future based on experiences from other viral infections, 
complemented this review in the discussion section. 
2. Material and methods 
Details of the protocol for this systematic review were registered on 
PROSPERO and can be accessed at www.crd.york.ac.uk/PROSPERO 
/display_record.asp?ID=CRD42020208725. 
2.1. Data sources and searches 
A systematic search of published papers and preprints was performed 
in the databases Embase, PubMed, Scopus, WHO, LitCovid, bioRxiv and 
medRxiv. The search terms were selected to find papers on sequelae to a 
SARS-CoV-2 infection and included the terms “COVID-19”, “coronavirus 
disease 2019”, “SARS-CoV-2”, “sequelae” and “consequence*”. The 
terms “child*” and “pregnant” served as negative qualifier. The online 
searches were performed between 15th and 17th September 2020. The 
complete search strategies are included in the Supplement (Appendix 1). 
2.2. Data management 
References found through the systematic search were imported into 
Mendeley, a reference management tool. After a first elimination of 
duplicates, a single reference file was generated and uploaded into the 
Covidence online tool, a non-profit service for screening and facilitating 
the systematic review process [2]. The assessment of inclusion or 
exclusion of every reference was performed by two out of eight inde-
pendent reviewers (N.B., N.H., A.H., R.L., C.S., D.S., K.S., S.W.) ac-
cording to predefined criteria. Only studies including original data and 
systematic or narrative reviews published up to 15th September 2020 
were included. Only English language papers were included. References 
including children (below the age of 18 years) or only elderly (age 50 
years and above) were excluded. The goal of this systematic review was 
to focus on young adults aged 18–50 years as they make up the majority 
of the working population. COVID-19 in this group was initially 
considered to be a mild illness. In the interim, evidence is emerging of 
persistent sequelae even in previously healthy young populations. Other 
systematic reviews have looked at COVID-19 sequelae in the elderly, the 
polymorbid or those who were hospitalized with severe illness. In such 
groups, it is more difficult to distinguish sequelae of COVID-19 from 
other disease progression. Children were excluded due their differing 
anatomy and physiology and their seemingly lower susceptibility to 
SARS-CoV-2 virus which makes it difficult to compare them to adults 
directly. Additionally, study subjects had to have a confirmed 
SARS-CoV-2 infection. Both sexes and formerly healthy participants as 
well as participants at risk (as defined by WHO [3]) were included. The 
study period had to include the follow-up after usual recovery and/or 
discharge from hospital. Animal, laboratory or in vitro studies were 
excluded. Any discrepancies were resolved by a third reviewer. The full 
text screening was performed by two independent reviewers (either K.S. 
and S. W. or N.B. and S. W.). Conflicts in the full text screening were 
resolved by discussion. The included studies were carefully screened for 
other references containing original data that fit the inclusion criteria 
and were missed by the systematic search. 
All the studies finally included were summarized in tables according 
to organ system. A bias assessment of all cohort and cross-sectional 
studies was performed by two independent reviewers (R.L. and S.W.) 
using a modified version of the Newcastle-Ottawa Scale (mNOS) for 
assessing the quality of non-randomized studies [4] as presented in the 
Supplement. Discrepancies were resolved by discussion. In addition, an 
analysis of the evidence level according to the JAMA network (modified 
from Oxford Centre for Evidence-based Medicine) was carried out for 
each study [5]. 
3. Results 
A total of 5229 references were retrieved during the search and 
imported into Mendeley where 2478 duplicates were removed. Covi-
dence recognized another 30 duplicates, leaving 2721 references for title 
and abstract screening. A total of 2540 references were deemed irrele-
vant during the title and abstract screening. Of the remaining 181 ref-
erences, 18 references containing original data were finally included 
during the full text review. Additionally, there were 13 studies identified 
through screening of the included references and through other sources. 
Fig. 1 shows the PRISMA flow chart diagram [6]. Included studies 
comprised of 11 prospective and 11 retrospective cohort studies, 4 
cross-sectional studies and 5 case reports. 
All the references included in this review were summarized in 
Table 1 including the study quality ratings from the modified Newcastle- 
Ottawa Scale. Scores were classified as unsatisfactory (0–3 points), 
satisfactory (4–5 points), good (6–7 points) and very good (8–9 points). 
A total of four studies were awarded “very good”, while five studies 
received a “good” rating. A majority of 12 studies were deemed “satis-
factory”. Five studies only received three points and therefore were 
rated as “unsatisfactory”. As the modified Newcastle-Ottawa Scale is not 
suitable for rating case reports, the remaining five case reports were only 
rated according to the evidence level as defined by the JAMA network 
[5]. The detailed rating of each study can be found in eTable 1 in the 
Supplement. 
Only information and subpopulations relevant for this review were 
listed. 
3.1. General health 
Two prospective and two retrospective cohort studies as well as three 
cross-sectional studies were grouped under the term “general health” 
[7–13]. 
The follow-up intervals lasted between 14 days and 12 weeks. Five 
out of these six studies reported persistent fatigue in 39–72% of study 
participants [7,9–12]. Breathlessness or shortness of breath was re-
ported by four out of six, ranging from 39 to 74% [7,8,10,11]. In five 
studies, a reduction in life quality or general health status was observed 
[7,8,10–12]. In one study, 31% of formerly employed participants have 
not returned to work at approximatively 72 days post-discharge [9]. 
Another study reported functional restrictions (e.g. changes in life-style, 
sports and social activities) in 80% of participants, albeit 63% thereof 
was considered negligible [13]. 
3.2. Respiratory system 
There were two prospective and eight retrospective cohort studies 
and one case report containing information regarding the respiratory 
system [14–24]. 
Eight out of 11 studies used computed tomography [16–19,21–24]. 
Six out of 11 performed a lung function test [14–16,20,23,24]. 
Follow-up intervals ranged from nine days to three months 
post-discharge from hospital. Abnormal CT findings were found in 
39–83% of study participants. Five studies described pulmonary fibrosis 
as a radiological finding [17,18,20,22,24], while hypoperfused lung 
volume was found in one study [19]. Impaired lung function was 
observed in 19–75% of the study population [14–16,20,23,24]. 
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3.3. Cardiovascular and hematological system 
References classified into the cardiovascular and hematological 
category included two prospective cohort studies, one cross-sectional 
study and one case report [25–28]. 
Time to follow-up examination varied from 11 days after quarantine 
to approximatively three months post-diagnosis. Three studies per-
formed cardiac magnetic resonance imaging and observed evidence of 
peri-, myoperi- and myocarditis in 3–26% of the participants [25–27]. 
One study showed altered immune cell counts 9–11 weeks after symp-
tom onset [25], while a case report described isolated thrombocytopenia 
in a patient approximatively one month after symptom onset [28]. 
3.4. Neurological system and mental health 
Two studies, a prospective cohort study and a case report, described 
neurological complications [29,30] while one prospective and one 
retrospective cohort study investigated psychiatric sequelae [31,32]. In 
one study, a MRI follow-up after three months showed disruptions to 
microstructural and functional brain integrity and 55% of participants 
complained about persistent neurological symptoms [29]. A case report 
showed persisting lower limb weakness one month after symptom onset 
[30]. An increased incidence of 5.8% of newly diagnosed psychiatric 
diseases 14–90 days after diagnosis of COVID-19 infection was shown in 
a large cohort study in comparison to a control group where 2.5–3.4% of 
participants received a new psychiatric diagnosis [31]. The other 
reference described a prevalence of at least one psychopathological 
dimension approximately one month post-discharge or after evaluation 
at the emergency department in 56% of study participants [32]. 
3.5. Otorhinolaryngological system 
A total of three prospective cohort studies examined olfactory and 
gustatory dysfunction after COVID-19 [33–35]. The follow-up intervals 
ranged from 12 to 39 days after symptom onset. There was a lack of 
recovery of gustatory and/or olfactory function in 3–13.9% of study 
participants. Incomplete recovery was observed in 33.6–36% of partic-
ipants at follow-up. 
3.6. Endocrinological system 
There were two case reports describing subacute thyroiditis (SAT) 15 
days and six weeks after symptom onset, respectively [36,37]. In both 
cases there was a clinical and laboratory resolution of SAT within two 
weeks of adequate therapy. 
4. Discussion 
There is an ever-expanding body of knowledge regarding the acute 
effects of a SARS-CoV-2 infection on several organs. So far, it is known 
that SARS-CoV-2 can infect lung, heart, liver and kidney tissue, gastro-
intestinal mucosa, vascular endothelium, macrophages, T-lymphocytes 
and neurons [38]. In addition to the direct damage through the viral 
infection, in some patients the infection leads to a massive release of 
cytokines, a cytokine storm, which indirectly results in extensive tissue 
damage [39]. As a consequence, in every affected organ, directly or 
Fig. 1. PRISMA flow diagram.  




Summary of references reporting long-term sequelae of COVID-19.  
Author, Year Title Journal Study type Participants Eligibility criteria Follow-up time Examination 
methods 




General Health  
Halpin et al., 
2020 [7] 
Postdischarge symptoms 
and rehabilitation needs 
in survivors of COVID-19 
infection: A cross- 
sectional evaluation 




68 ward patients 
(20-93y, 48.5% 




Treated for COVID- 
19 within Leeds 
Teaching Hospitals 
NHS Trust; RT-PCR 
confirmed 





Illness-related fatigue (72% 
ICU group, 60.3% ward 
group); breathlessness 
(65.6% in ICU group, 42.6% 
ward group); psychological 
distress (46.9% ICU, 23.5% 
ward group); 
drop in the EQ-5D instrument 




et al., 2020 
[8] 
Post-discharge health 
status and symptoms in 







>18y old; required 
at least 6l O2 during 
hospital stay; RT- 
PCR confirmed 





Shortness of breath 74.3%; 
drop of 1 out of 5 points in 








infection is common and 





49.5± 15y, 54% 
female) 
At least 6 weeks 
after date of last 
acute symptom 
(outpatient) or date 
of discharge; 
RT-PCR confirmed 







Persistent fatigue 52.3%; 
formerly employed not 
returned to work 31% 
6 4a 
Arnold et al., 
2020 [10] 
Patient outcomes after 
hospitalization with 
COVID-19 and 
implications for follow- 
up; results from a 
prospective UK cohort. 
Preprint Prospective 
cohort study 
110 (ICR 46- 
73y) 
>18y old; RT-PCR 
confirmed or clinic- 
radiological 
diagnosis 




exercise test, blood 
test, HRQoL 
questionnaire 
At least one persistent 
symptom 74%; including 
breathlessness (39%), 
excessive fatigue (39%) and 
insomnia (24%); 2 with 
fibrotic changes in HRCT; 11 
with restrictive pattern 
spirometry; 15 with 
desaturation in sit-to-stand 
test; reduced SF-36 health 
status 
5 3a 
Carfi et al., 
2020 [11] 
Persistent Symptoms in 






Diagnosis of COVID- 
19; negative test at 
study begin 
Mean of 60 days 






Persistent symptoms 87.4% 
(fatigue 53.1%, dyspnea 
43.3%, joint pain 27.3%, 
chest pain 21.7%); Worsened 
quality of life 44.1% 
6 3 
Tenforde 
et al., 2020 
[12] 
Symptom Duration and 
Risk Factors for Delayed 
Return to Usual Health 
Among Outpatients with 
COVID-19 in a Multistate 
Health Care Systems 

















after test date 
Telephone 
interviews 
One or more symptoms 94% 
(fatigue 71%, cough 61%, 
headache 61%); among 
symptomatic responders not 
returned to usual state of 
health 35% (26% among 
those aged 18-34y, 32% 





















days since onset 
of symptoms 




80% of recovered with 
diverse degrees of functional 
restrictions (63.1% 
negligible, 14.4% slight, 2% 
moderate, 0.5% severe) 
4 4a 
Respiratory System 
(continued on next page) 
S. W
illi et al.                                                                                                                                                                                                                                     
TravelMedicineandInfectiousDisease40(2021)101995
5
Table 1 (continued ) 
Author, Year Title Journal Study type Participants Eligibility criteria Follow-up time Examination 
methods 




Crameri et al., 
2020 [14] 
Reduced maximal aerobic 
capacity after COVID-19 
in young adult recruits, 
Switzerland, May 2020 









19% of COVID- 19 
convalescents with decrease 
of >10% in VO2 max 
8 3 
Frija-Masson 
et al., 2020 
[15] 
Functional characteristics 
of patients with SARS- 



















27/50 with impaired lung 
function, mix of restrictive 
and low diffusion patterns 
6 3 
Zhao et al., 
2020 [16] 
Follow-up study of the 
pulmonary function and 
related physiological 
characteristics of COVID- 




55 (mean age 
47y, SD 15.49, 
41.82% female) 
Diagnosis according 
to WHO interim 
guidance 
3 months post- 
discharge 
HRCT, lung function Radiological abnormalities 
70.91%; lung function 
abnormalities (e.g. diffusion 
reductions in DLCO) 25.45%; 
persistent gastrointestinal 
symptoms 31%, headache 
18.18%, fatigue 16.36%, 
exertional dyspnea 14.55% 
5 3 
Wei et al., 
2020 [17] 
Analysis of thin-section 
CT in patients with 
coronavirus disease 
(COVID-19) after hospital 
discharge 





59 (25-70y, 28/ 
59 female) 




Residual pulmonary fibrosis 
39% 
3 3 
Yu et al., 2020 
[18] 
Prediction of the 
Development of 
Pulmonary Fibrosis Using 
Serial Thin-Section CT 
and Clinical Features in 
Patients Discharged after 
Treatment for COVID-19 








and discharged; at 
least 2x thin-section 
CT during 
hospitalization 
9 days post- 
discharge (20 




14/32 with signs of 
pulmonary fibrosis 
3 3 
Patelli et al., 
2020 [19] 
Preliminary detection of 
lung hypoperfusion in 
discharged Covid-19 
patients during recovery 




20 (35-86y, 8/ 
20 female) 
Treated for SARS- 
CoV-2 pneumonia 
14–60 days after 
remission of 
fever 
Chest CT 8/20 with residual dyspnea 
associated with 
hypoperfused lung volume 
5 3 
You et al., 
2020 [20] 
Anormal pulmonary 
function and residual CT 
abnormalities in 
rehabilitating COVID-19 
patients after discharge 
Journal of Infection Prospective 
cohort study 
18 (28-67y, 8/ 
18 female) 







5/12 non-severe and 2/5 
severe patients with 
abnormal lung function; 83% 









IDCases Case report 50y man – 1 month after 
symptom onset 




Liu et al., 2020 
[22] 
The pulmonary sequelae 
in discharged patients 
with COVID-19: A short- 
term observational study 







1, 2 and 3 weeks 
post-discharge 
Chest CT Incomplete radiological 
resolution (residual fibrous 
stripes) 47% in 3rd week 
3 3 












82 (mean 57y, 
36.6% female) 




test, lung function, 
thoracic CT, 
echocardiography 
66% with persistent 
symptoms (dyspnea, cough); 
24% with persistent lung 




Respiratory Research 4 3 
(continued on next page) 
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Table 1 (continued ) 
Author, Year Title Journal Study type Participants Eligibility criteria Follow-up time Examination 
methods 




Huang et al., 
2020 [24] 
Impact of coronavirus 
disease 2019 on 
pulmonary function in 
early convalescence phase 
Retrospective 
cohort study 
57 (19-71y, 31/ 
57 female) 




>30 days post- 
discharge 
CT, lung function 
tests, 6 min walk test 
Abnormal CT findings 54.3%; 
abnormal pulmonary 
function tests 75.4%; 4/57 
with pulmonary fibrosis 
Cardiovascular & Haematological System 
Eiros et al., 
2020 [25] 
Pericarditis and 
myocarditis long after 
SARS-CoV-2 infection: a 
cross-sectional descriptive 




139 (IQR 41- 
57y, 72% 
female) 





ECG, blood test, 
CMR 
Diagnosis of pericarditis in 
3%, myopericarditis in 11%, 
myocarditis in 26%; 42% 
with chest pain, dyspnea or 
palpitations; 50% with ECG 
abnormalities; 75% with 
CMR abnormalities; 73% 
with altered immune cell 
counts in blood 
8 4a 
Puntmann 




Resonance Imaging in 
Patients Recently 
Recovered from 
Coronavirus Disease 2019 
(COVID-19) 
JAMA Cardiology Prospective 
cohort study 






swab test at end of 
isolation period 
64–92 days post- 
diagnosis 
CMR, blood test 78% with abnormal CMR, 
60% with ongoing 
myocardial inflammation 
8 3 
Rajpal et al., 
2020 [27] 
Cardiovascular Magnetic 
Resonance Findings in 
Competitive Athletes 
Recovering From COVID- 
19 Infection 
JAMA Cardiology Prospective 
cohort study 




11–53 days after 
recommended 
quarantine 
CMR, ECG, blood 
test, 
echocardiogram 
CMR findings consistent with 
myocarditis in 15%; CMR 
findings suggesting prior 
myocardial injury in 30.8% 
3 3 
Chen et al., 
2020 [28] 
Sudden severe 
thrombocytopenia in a 
patient in the recovery 
stage of COVID-19. 
The Lancet 
Haematology 
Case report 38y male – 29 days after 
symptom onset 
Blood test Isolated thrombocytopenia 
(resolution through therapy 
in 2 weeks) 
– 5 
Neurological System & Mental Health 
Lu et al., 2020 
[29] 
Cerebral Micro-Structural 
Changes in COVID-19 
Patients, An MRI-based 3- 
month Follow-up Study: A 
brief title: Cerebral 
Changes in COVID-19 
EClinicalMedicine Prospective 
cohort study 




hospital in Fuyang 
3 months MRI, questionnaire Possible disruption to micro- 
structural and functional 
brain integrity; 55% with 
persistent neurological 
symptoms (headache, 
memory loss, myalgia, mood 
change) 
8 3 
Morjaria et al., 
2020 [30] 
Bilateral lower limb 
weakness: a 
cerebrovascular 
consequence of covid-19 
or a complication 
associated with it? 
Internal and 
Emergency Medicine 




Persisting lower limb 
weakness 
– 5 
Taquet et al., 
2020 [31] 
Bidirectional associations 
between COVID-19 and 
psychiatric disorder: a 




44′779 out of a 
cohort of 62′354 
(mean 49.3y, 
55.3% female) 
Diagnosis of COVID- 
19 or pneumonia 
due to SARS- 
associated 
coronavirus, other 
coronavirus as cause 
of disease, 
coronavirus 
14–90 days after 
diagnosis 
Statistical analysis of 
cohort studies 




5.8% vs. 2.5–3.4% in control 
6 3a 
(continued on next page) 
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Table 1 (continued ) 
Author, Year Title Journal Study type Participants Eligibility criteria Follow-up time Examination 
methods 






Mazza et al., 
2020 [32] 
Anxiety and depression in 
COVID-19 survivors: Role 
of inflammatory and 
clinical predictors 






COVID-19 survivors 31.29±15.7 days 
post-discharge or 
28.56±11.73 






56% in clinical range of at 
least 1 psychopathological 
dimension (28% PTSD, 31% 
depression, 42% anxiety, 




Chary et al., 
2020 [33] 
Prevalence and Recovery 
From Olfactory and 
Gustatory Dysfunctions in 
Covid-19 Infection: A 
Prospective Multicenter 
Study. 
American Journal of 









36% with incomplete 
olfactory (anosmia, 
hyposmia) or gustatory 
(ageusia, hypogeusia) 
recovery, 3% with lack of 
recovery 
4 3 
Kosugi et al., 
2020 [34] 
Incomplete and late 
recovery of sudden 
olfactory dysfunction in 
COVID-19. 









– 12-39 (median 
31) days after 
symptom onset 
Online survey for 
physicians 
No recovery in 13.9% and 
partial recovery in 33.6% 
with loss of olfaction 
7 3 
Lechien et al., 
2020 [35] 
Olfactory and gustatory 
dysfunctions as a clinical 
presentation of mild-to- 













>18y old; RT-PCR 
confirmed 
>15 days after 
onset of infection 
Questionnaire Anosmia recovery time > 15 
days in 3.4% 
4 3 
Endocrinological System 
Ruggeri et al., 
2020 [36] 
Subacute thyroiditis in a 
patient infected with 
SARS-COV-2: an 
endocrine complication 
linked to the COVID-19 
pandemic 










et al., 2020 
[37] 
Subacute Thyroiditis After 
Sars-COV-2 Infection. 










(resolution with therapy in 2 
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indirectly, there is the possibility of persistent damage with specific 
sequelae. 
In this systematic review we provide an evaluation of data con-
cerning COVID-19 intermediate and long-term sequelae published to 
date. This paper focuses on sequelae in previously healthy individuals. 
As COVID-19 is a relatively new disease entity the follow-up time in 
studies identified in our systematic search does not exceed 12 weeks. It is 
currently not possible to predict the longer-term impact of several 
months to years. It is conceivable that a lot of outcomes seen in the more 
short-term frame of two to six weeks are of transient nature. The WHO 
proposes a recovery time of up to two weeks for mild and up to six weeks 
for severe disease courses [40]. 
Our review, however, shows that a significant proportion of formerly 
healthy adults aged 18–50 years is affected by COVID-19 sequelae for 
longer periods. As they make up the majority of the working population, 
there will be longer term consequences and burdens not only for the 
health system but also for the economy. 
4.1. General health 
Regarding general health, there seems to be mounting evidence that 
a considerable number of COVID-19 convalescents will suffer from fa-
tigue even weeks after the acute infection has subsided. Post-infectious 
fatigue months and even years after recovery has been previously 
observed in a variety of viral infections. There is evidence of chronic 
fatigue as a long-term consequence, especially in people younger than 
30 years old, after epidemics of influenza A(H1N1) virus, SARS-CoV, 
Ebolavirus and West Nile virus. In some of these cases, the diagnostic 
criteria for Chronic Fatigue Syndrome were fulfilled. A miscommuni-
cation in the inflammatory response pathways, especially cytokine 
networks, might be the underlying cause [41]. It has been hypothesized 
that a COVID-19 infection might lead to a higher predisposition for a 
number of different cancer types. Hays et al. proposed an increased 
tumorigenesis through the activation of the MAPK and JAK-STAT 
pathway upon a COVID-19 infection and the weakened immune sys-
tem following a cytokine storm [39]. 
4.2. Respiratory system 
As seen in the results section, abnormalities in pulmonary function 
were observed in the lung function examination (e.g. as decrease in 
aerobic capacity or reduction in diffusion capacity) as well as radio-
logically. Even though a majority of patients recovered fully or were in 
the process of radiological and/or clinical resolution, it would not be 
surprising if lung damage in the form of residual pulmonary fibrosis 
persisted in the long-term. This would also be a plausible explanation as 
to why some patients experienced shortness of breath even at up to 12 
weeks after hospital admission [10]. Again, there is evidence from the 
SARS and MERS pandemic that some patients experienced lung damage 
up to 15 years later [42]. 
4.3. Cardiovascular and hematological system 
According to the studies found in this review, cardiac damage might 
be a significant long-term sequela. Myocarditis, perimyocarditis and 
pericarditis were diagnosed as late as 11 weeks after symptom of 
infection onset [25]. Rajpal et al. showed that cardiac consequences 
were also pronounced in younger athletes [27]. This is especially con-
cerning as myocarditis can lead to sudden cardiac death. Even with 
apparently recovered cardiac function, there might still be a risk of 
coronary artery disease, atrial fibrillation or ventricular arrhythmias as a 
consequence of myocardial injury [43]. 
4.4. Neurological system and mental health 
To date, there are few original data on neurological sequelae. 
Radiologically, there seem to be distinct changes in cerebral micro- 
structure, especially in those areas related to memory and smell loss, 
compared to healthy controls [29]. However, there is widespread 
speculation concerning neurological long-term consequences [38, 
44–46]. Several authors speculate that SARS-CoV-2 might trigger 
neurodegenerative diseases like multiple sclerosis, Parkinson’s disease 
and narcolepsy in predisposed individuals in the long-term [44–46]. The 
occurrence of anosmia and ageusia in some patients has even been 
associated with prodromal features of Parkinson’s disease [44]. 
With over 44′000 study subjects, Taquet et al. performed the most 
extensive study in this review in terms of numbers [31]. They observed a 
significant increase in newly diagnosed psychiatric diseases like anxiety, 
depression, insomnia and dementia compared to an unaffected control 
group. Likewise, Mazza et al. found indications of at least one psychi-
atric disease (post-traumatic stress disorder, depression, anxiety, 
obsessive-compulsive disorder, insomnia) in 56% of study participants 
approximatively 30 days post-discharge. Extrapolated from experiences 
with SARS and MERS, where the prevalence of depression, anxiety and 
post-traumatic stress disorder was high even after 39 months, a 
considerable impact on mental health post COVID-19 should be antici-
pated [47]. 
4.5. Otorhinolaryngological system 
All three included studies investigating olfactory and gustatory 
dysfunction found a lack of or incomplete recovery in a substantial part 
of participants. However, they have a rather short follow-up period of 
only two to five weeks. Imam et al. believe that COVID-19 related ol-
factory dysfunction follows a similar mechanism as the post-viral ol-
factory dysfunction seen with other viral infections such as influenza 
virus, rhinovirus, metapneumovirus or parainfluenza virus. So these 
sequelae may reduce over longer time periods [48]. 
4.6. Endocrinological and reproductive system 
Concerning the endocrinological system, only two case reports were 
found of whom both described a case of subacute thyroiditis following a 
COVID-19 infection. As this constitutes only sparse evidence, a state-
ment regarding the scope of long-term sequelae in this organ system 
cannot be made. Nevertheless, Mongioi ̀ et al. hypothesize a role of SARS- 
CoV-2 in pancreatic damage and subsequent development of diabetes, in 
hypothalamic-pituitary-adrenal axis dysfunction and adrenal insuffi-
ciency and in hypothalamic-pituitary-thyroid axis dysfunction with 
thyroid damage, as seen in SARS-CoV infection [49]. As ACE2 is highly 
expressed by the human testis, an infection might lead to testicular 
damage and associated male infertility [49,50]. 
4.7. Strengths and limitations 
To our knowledge, this is the first systematic review on long-term 
sequelae of COVID-19. The strengths of our systematic review include 
the careful and thorough searches according to PRISMA guidelines and 
the thorough extraction and interpretation of selected papers. A further 
strength is the quality assessment of articles using the modified 
Newcastle-Ottawa Scale as well as the pyramid of evidence. A limitation 
of our work, common to all research on COVID-19 consequences, is the 
limited time frame to assess sequelae as the interval since the beginning 
of the COVID-19 pandemic and this systematic review is just seven 
months, allowing scant time for the evolution of longer-term implica-
tions. Due to the fact that there is a limited number of references as of 
yet, we did not investigate geographic differences in type of COVID-19 
sequelae. 
5. Conclusions 
Even though our current knowledge suggests that most COVID-19 
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sequelae in young, previously healthy adults, are of transient nature, 
there are indications of multi-organ impact. The large global burden of 
cases worldwide suggests that we will most likely face an ongoing wave 
of COVID-19 sequelae. Close attention should be paid to residual im-
pairments in multi-organ function, especially persistent reduced lung 
function and carditis, and to mental health and neurological sequelae 
including post-viral fatigue syndrome. We suggest that further research 
should include lung function tests and sensitive test batteries to detect 
long-lasting structural and functional damage to the cardiopulmonary 
and the neurological system. Patients suffering from post-viral fatigue 
syndrome and mental health impairments could be followed-up 
routinely with questionnaires to monitor disease course. In general, 
study test batteries to follow up on sequelae should be carefully designed 
to detect subtle, long-term sequelae. 
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[37] Brancatella A, Ricci D, Viola N, Sgrò D, Santini F, Latrofa F. Subacute thyroiditis 
after sars-COV-2 infection. J Clin Endocrinol Metab 2020:105. 
S. Willi et al.                                                                                                                                                                                                                                     
Travel Medicine and Infectious Disease 40 (2021) 101995
10
[38] Fenrich M, Mrdenovic S, Balog M, Tomic S, Zjalic M, Roncevic A, et al. SARS-CoV-2 
dissemination through peripheral nerves explains multiple organ injury. Front Cell 
Neurosci 2020;14. https://doi.org/10.3389/fncel.2020.00229. 
[39] Hays P. Clinical sequelae of the novel coronavirus: does COVID-19 infection 
predispose patients to cancer? Future Oncol 2020;16:1463–74. https://doi.org/ 
10.2217/fon-2020-0300. 
[40] World Health Organization. Report of the WHO-China joint mission on coronavirus 
disease 2019 (COVID-19). 2020. 
[41] Islam MF, Cotler J, Jason LA. Post-viral fatigue and COVID-19: lessons from past 
epidemics. Fatigue Biomed Heal Behav 2020;8:61–9. https://doi.org/10.1080/ 
21641846.2020.1778227. 
[42] Helding L, Carroll TL, Nix J, Johns MM, LeBorgne WD, Meyer D. COVID-19 after 
effects: concerns for singers. J Voice 2020. https://doi.org/10.1016/j. 
jvoice.2020.07.032. 
[43] Mitrani RD, Dabas N, Goldberger JJ. COVID-19 cardiac injury: implications for 
long-term surveillance and outcomes in survivors. Heart Rhythm 2020. https://doi. 
org/10.1016/j.hrthm.2020.06.026. 
[44] Schirinzi T, Landi D, Liguori C. COVID-19: dealing with a potential risk factor for 
chronic neurological disorders. J Neurol 2020. https://doi.org/10.1007/s00415- 
020-10131-y. 
[45] Vonck K, Garrez I, De Herdt V, Hemelsoet D, Laureys G, Raedt R, et al. Neurological 
manifestations and neuro-invasive mechanisms of the severe acute respiratory 
syndrome coronavirus type 2. Eur J Neurol 2020;27:1578–87. https://doi.org/ 
10.1111/ene.14329. 
[46] Yachou Y, El Idrissi A, Belapasov V, Ait Benali S. Neuroinvasion, neurotropic, and 
neuroinflammatory events of SARS-CoV-2: understanding the neurological 
manifestations in COVID-19 patients. Neurol Sci 2020;41:2657–69. 
[47] Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. 
Psychiatric and neuropsychiatric presentations associated with severe coronavirus 
infections: a systematic review and meta-analysis with comparison to the COVID- 
19 pandemic. Lancet Psychiatry 2020;7:611–27. 
[48] Imam SA, Lao WP, Reddy P, Nguyen SA, Schlosser RJ. Is SARS-CoV-2 (COVID-19) 
postviral olfactory dysfunction (PVOD) different from other PVOD? World J 
Otorhinolaryngol Head Neck Surg 2020. https://doi.org/10.1016/j. 
wjorl.2020.05.004. 
[49] Mongioì LM, Barbagallo F, Condorelli RA, Cannarella R, Aversa A, La Vignera S, 
et al. Possible long-term endocrine-metabolic complications in COVID-19: lesson 
from the SARS model. Endocrine 2020;68:467–70. https://doi.org/10.1007/ 
s12020-020-02349-7.LK. 
[50] Dutta S, Sengupta P. SARS-CoV-2 and male infertility: possible multifaceted 
pathology. Reprod Sci 2020. https://doi.org/10.1007/s43032-020-00261-z. 
S. Willi et al.                                                                                                                                                                                                                                     
